Therefore, early identification of ClC‐5 mutations in patients with proteinuria and/or hypercalciuria, and an improved understanding of the consequences of disease‐associated mutations on CLC‐5 function, biosynthesis, endosomal trafficking, stability, and function are vital for the development of effective targeted therapies. This evidence concerns the gene CLCN5 and Hypercalciuria.